Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · DuoResp Spiromax
DuoResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder · Abschnitt 4.5 · PDF-Seite 9
HOS-215192 · Präparat HOS-155404
Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines
(terfenadine) and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular
arrhythmias.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quinidine (HOS-085593) disopyramide (HOS-085595) procainamide (HOS-086617) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-24T17:52:00Z · SHA-256 42079bf4b69044dc4d633d260c46172c183d9e017cb9bfa60f9313d810771afa · Passage a4eeb4ecf892aed9b44dd2b4d09a773ab951b84b183aeee4574a0176b7f93c74 · Zeichen 1981–2200 im Abschnitt
Wechselwirkungen · DuoResp Spiromax
DuoResp Spiromax 320 micrograms/9 micrograms inhalation powder · Abschnitt 4.5 · PDF-Seite 24
HOS-215224 · Präparat HOS-155404
Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines
(terfenadine) and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular
arrhythmias.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quinidine (HOS-085593) disopyramide (HOS-085595) procainamide (HOS-086617) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-24T17:52:00Z · SHA-256 42079bf4b69044dc4d633d260c46172c183d9e017cb9bfa60f9313d810771afa · Passage a4eeb4ecf892aed9b44dd2b4d09a773ab951b84b183aeee4574a0176b7f93c74 · Zeichen 1754–1973 im Abschnitt
Wechselwirkungen · Bosulif
Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets Bosulif 50 mg hard capsules Bosulif 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-125464 · Präparat HOS-096073
Anti-arrhythmic medicinal products and other substances that may prolong QT
Bosutinib should be used with caution in patients who have or may develop prolongation of QT,
including those patients taking anti-arrhythmic medicinal products such as amiodarone, disopyramide,
procainamide, quinidine and sotalol or other medicinal products that may lead to QT prolongation
such as chloroquine, halofantrine, clarithromycin, domperidone, haloperidol, methadone, and
moxifloxacin (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) methadone (HOS-086198) halofantrine (HOS-085606) quinidine (HOS-085593) domperidone (HOS-114656) lead (HOS-085592) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) bosutinib (HOS-109449) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:15:00Z · SHA-256 86c38605c3386630b4591643bb4507bc13ee17f96b594c991ef48865ec55c6c0 · Passage 88161ea85dfeb23e4b9e9c602a7dfea6a9d42372a9e1a9e087175c891fc2cac6 · Zeichen 4936–5427 im Abschnitt
Wechselwirkungen · Xalkori
XALKORI 200 mg hard capsules XALKORI 250 mg hard capsules XALKORI 20 mg granules in capsules for opening XALKORI 50 mg granules in capsules for opening XALKORI 150 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 16
HOS-126291 · Präparat HOS-096239
In clinical studies, prolonged QT interval was observed with crizotinib. Therefore, the concomitant use
of crizotinib with medicinal products known to prolong QT interval or medicinal products able to
induce Torsades de pointes (e.g., class IA [quinidine, disopyramide] or class III [e.g., amiodarone,
sotalol, dofetilide, ibutilide], methadone, cisapride, moxifloxacine, antipsychotics, etc.) should be
carefully considered. A monitoring of the QT interval should be made in case of combinations of such
medicinal products (see sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) cisapride (HOS-085610) methadone (HOS-086198) dofetilide (HOS-085598) ibutilide (HOS-085599) quinidine (HOS-085593) disopyramide (HOS-085595) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-17T11:44:00Z · SHA-256 ef70dd9e8f617f709767e5bd4c7044eb23893a7ac40281434ebfa2fb8fb4e3d5 · Passage 816aeccce87161f28299d2111ef7fc1cff699bf0f238742f6130dab49d58a230 · Zeichen 6388–6939 im Abschnitt
Wechselwirkungen · Xtandi
Xtandi - 40 mg soft capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-127890 · Präparat HOS-096479
Medicinal products which prolong the QT interval
Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Xtandi with
medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de
pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide,
ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be
carefully evaluated (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) methadone (HOS-086198) dofetilide (HOS-085598) ibutilide (HOS-085599) quinidine (HOS-085593) disopyramide (HOS-085595) moxifloxacin (HOS-085604) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 2f7b39cdc55c939d0537da888c075342ddb5cd817e33ae5684dcbf5616a96c42 · Zeichen 8414–8912 im Abschnitt
Wechselwirkungen · Xtandi
Xtandi - 40 mg film-coated tablets Xtandi - 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 37
HOS-127933 · Präparat HOS-096479
Medicinal products which prolong the QT interval
Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Xtandi with
medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de
pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide,
ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be
carefully evaluated (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) methadone (HOS-086198) dofetilide (HOS-085598) ibutilide (HOS-085599) quinidine (HOS-085593) disopyramide (HOS-085595) moxifloxacin (HOS-085604) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 2f7b39cdc55c939d0537da888c075342ddb5cd817e33ae5684dcbf5616a96c42 · Zeichen 8415–8913 im Abschnitt
Wechselwirkungen · Latuda
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-128655 · Präparat HOS-096607
Caution is advised when prescribing lurasidone with medicinal products known to prolong the QT
interval, e.g. class IA antiarrhythmics (e.g. quinidine, disopyramide) and class III antiarrhythmics (e.g.
amiodarone, sotalol), some antihistaminics, some other antipsychotics and some antimalarials (e.g.
mefloquine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) quinidine (HOS-085593) disopyramide (HOS-085595) amiodarone (HOS-085596) mefloquine (HOS-113850)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage 6f2b687d09e4b9b51f0b747bcc6b4d31d349d3a1d39e6fc4237bfeb65f0e10e5 · Zeichen 208–521 im Abschnitt
Wechselwirkungen · Abasaglar (previously Abasria)
ABASAGLAR 100 units/mL solution for injection in a cartridge · Abschnitt 4.5 · PDF-Seite 6
HOS-130160 · Präparat HOS-096865
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates, somatostatin anologues and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) pentoxifylline (HOS-088586) disopyramide (HOS-085595) fluoxetine (HOS-085946) somatostatin (HOS-110277)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-13T13:04:00Z · SHA-256 8a48895fa1a195b1b88589b8cd0ee2e2b7b31cd9b013ed1703865e2f5891fd58 · Passage 6f1c277d9ea3c2d26543b1c43228e17e9e7bc69227f8c98842e795ad93a5bf11 · Zeichen 103–471 im Abschnitt
Wechselwirkungen · Abasaglar (previously Abasria)
ABASAGLAR 100 units/mL KwikPen solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 20
HOS-130203 · Präparat HOS-096865
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates, somatostatin anologues and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) pentoxifylline (HOS-088586) disopyramide (HOS-085595) fluoxetine (HOS-085946) somatostatin (HOS-110277)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-13T13:04:00Z · SHA-256 8a48895fa1a195b1b88589b8cd0ee2e2b7b31cd9b013ed1703865e2f5891fd58 · Passage 6f1c277d9ea3c2d26543b1c43228e17e9e7bc69227f8c98842e795ad93a5bf11 · Zeichen 103–471 im Abschnitt
Wechselwirkungen · Farydak
Farydak 10 mg hard capsules Farydak 15 mg hard capsules Farydak 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-130465 · Präparat HOS-096923
Prolongation of QT interval
Based on preclinical and clinical data, panobinostat has the potential to prolong the QT interval.
Concomitant use of anti-arrhythmic medicinal products (including, but not limited to, amiodarone,
disopyramide, procainamide, quinidine and sotalol) and other substances that are known to prolong the
QT interval (including, but not limited to, chloroquine, halofantrine, clarithromycin, methadone,
moxifloxacin, bepridil and pimozide) is not recommended. Anti-emetic medicinal products with a
known risk of QT prolongation such as dolasetron, granisetron, ondansetron and tropisetron should be
used with caution (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) methadone (HOS-086198) granisetron (HOS-086051) bepridil (HOS-085612) halofantrine (HOS-085606) quinidine (HOS-085593) tropisetron (HOS-130469) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) panobinostat (HOS-130447) pimozide (HOS-085600) moxifloxacin (HOS-085604) amiodarone (HOS-085596) dolasetron (HOS-112533) ondansetron (HOS-086052) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-01T17:42:00Z · SHA-256 58ca307f8694fb48a8bc74d8804d492564d6c11554c366f3220bc8e9fa2ab9be · Passage 6928758df33602ffbc0f5555b5d36091f6d50d6a0833c97770442ae3a8d31172 · Zeichen 3381–4038 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 9
HOS-131702 · Präparat HOS-097124
In clinical studies, QT prolongation was observed with ceritinib. Therefore, ceritinib should be used
with caution in patients who have or may develop prolongation of the QT interval, including those
patients taking anti-arrhythmic medicinal products such as class I (e.g. quinidine, procainamide,
disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics or other
medicinal products that may lead to QT prolongation such as domperidone, droperidol, chloroquine,
halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin. Monitoring of the
QT interval is indicated in the event of combinations of such medicinal products (see sections 4.2 and
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) cisapride (HOS-085610) methadone (HOS-086198) droperidol (HOS-087801) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) domperidone (HOS-114656) lead (HOS-085592) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 40eae0cde8e04371791e5e3fd69248b7ef61350ffe5b042411f9596daa975d64 · Zeichen 7488–8195 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-131756 · Präparat HOS-097124
In clinical studies, QT prolongation was observed with ceritinib. Therefore, ceritinib should be used
with caution in patients who have or may develop prolongation of the QT interval, including those
patients taking anti-arrhythmic medicinal products such as class I (e.g. quinidine, procainamide,
disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics or other
medicinal products that may lead to QT prolongation such as domperidone, droperidol, chloroquine,
halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin. Monitoring of the
QT interval is indicated in the event of combinations of such medicinal products (see sections 4.2 and
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) cisapride (HOS-085610) methadone (HOS-086198) droperidol (HOS-087801) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) domperidone (HOS-114656) lead (HOS-085592) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 40eae0cde8e04371791e5e3fd69248b7ef61350ffe5b042411f9596daa975d64 · Zeichen 7490–8197 im Abschnitt
Wechselwirkungen · Zydelig
Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132100 · Präparat HOS-097192
Bepridil, disopyramide, ↑ serum concentrations Clinical monitoring is recommended.
lidocaine
ANTI-CANCER AGENTS
Tyrosine kinase inhibitors such ↑ serum concentrations Careful monitoring of the tolerance to
as dasatinib and nilotinib, also these anti-cancer agents is
vincristine and vinblastine recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) lidocaine (HOS-108866) vinblastine (HOS-086220) bepridil (HOS-085612) vincristine (HOS-086219) disopyramide (HOS-085595) tyrosine (HOS-108875) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-21T17:52:00Z · SHA-256 f55f90ba278a87ef1c8e7162344ed4bd66ac7180deaf4c8fda3eca5bbf8e87e5 · Passage dcefc8756545ab9596bcdf86165a73d7cedb48f09cdf62c4f5f6d9d4ce436e7e · Zeichen 3532–3944 im Abschnitt
Gegenanzeigen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-132828 · Präparat HOS-097310
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1;
- Hypersensitivity to any imidazole antifungal medicinal product;
- Acute or chronic liver disease and/or if pre-treatment liver enzymes levels are above 2 times the upper
limit of normal (see sections 4.2 and 4.4):
- Pregnancy (see section 4.6);
- Breastfeeding (see section 4.6);
- Congenital or documented acquired QTc prolongation ;
- Concomitant therapy with any of the following medicinal products which may interact and result in
potentially life-threatening adverse reactions (see section 4.5):
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and
lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential:
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir
(saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and
methylergometrine (methylergonovine) due to an increased risk of ergotism and other serious
vasospastic adverse reactions;
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk
of hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) imidazole (HOS-117862) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) ergotamine (HOS-086154) ritonavir (HOS-084521) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage f9d16641f2e5b06b321fa0c79f0dacdfede818d20585398b4d37ddb19dad6a14 · Zeichen 0–2044 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132842 · Präparat HOS-097310
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin)
due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential :
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir
1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine
(methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse
reactionsevents
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of
hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of
these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) solifenacin (HOS-116433) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) ombitasvir (HOS-110300) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) colchicine (HOS-086147) everolimus (HOS-086310) fesoterodine (HOS-116432) sirolimus (HOS-085172) ergotamine (HOS-086154) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) ranolazine (HOS-086141) irinotecan (HOS-112102) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 0b65d259964c6f340994be44a864bad55b31283e3fc412d0d5a47323a792d889 · Zeichen 171–2105 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-132854 · Präparat HOS-097310
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Analgesic opioid
Methadone Potential ↑ in plasma concentrations of Contraindicated due to the increased
methadone risk of serious cardiovascular events
including QT prolongation and
torsade de pointes, or respiratory or
CNS depression (see section 4.3).
Buprenorphine IV and Buprenorphine: Careful monitoring.
sublingual AUC: ↑ 1.5-fold The buprenorphine dose should be
Cmax: ↑1.7-fold adjusted.
Alfentanil, fentanyl Potential ↑in plasma concentrations of Careful monitoring of adverse
alfentanil and fentanyl reactions (respiratory depression,
sedation) is recommended. It may be
necessary to lower the dose of
alfentanil and fentanyl.
Oxycodone ↑in plasma concentrations of oxycodone Careful monitoring.
have been observed The oxycodone dose may be
adjusted.
Antiarrhythmics
Disopyramide Potential ↑in plasma concentrations of Contraindicated due to the risk of
Quinidine disopyramide and quinidine serious cardiovascular events
including QT prolongation (see
Dronedarone Repeated doses of 200 mg ketoconazole section 4.3).
daily resulted in a 17-fold increase in
dronedarone exposure
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) dronedarone (HOS-086144) methadone (HOS-086198) oxycodone (HOS-109487) quinidine (HOS-085593) buprenorphine (HOS-086193) disopyramide (HOS-085595) fentanyl (HOS-086196)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage a1dd81238eab9495ccc07c3bae05807a0a25b388887cce3d7c2818dcf0cb8b03 · Zeichen 5148–7488 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-134000 · Präparat HOS-097520
16
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas levels. co-administration with Genvoya
Mean percent change in AUC,
Cmax, Cmin1
ANTIARRHYTHMICS
Digoxin (0.5 mg single dose)/ Digoxin: It is recommended that digoxin
Cobicistat (150 mg multiple doses) AUC: ↔ levels be monitored when digoxin is
Cmax: ↑ 41% combined with Genvoya.
Disopyramide Interaction not studied with any of Caution is warranted and clinical
Flecainide the components of Genvoya. monitoring is recommended upon
Systemic lidocaine co-administration with Genvoya.
Mexiletine Concentrations of these
Propafenone antiarrhythmic drugs may be
increased when co-administered
with cobicistat.
ANTI-HYPERTENSIVES
Metoprolol Interaction not studied with any of Clinical monitoring is recommended
Timolol the components of Genvoya. and a dose decrease may be
necessary when these agents are
Concentrations of beta-blockers co-administered with Genvoya.
may be increased when
co-administered with cobicistat.
Amlodipine Interaction not studied with any of Clinical monitoring of therapeutic
Diltiazem the components of Genvoya. effects and adverse reactions is
Felodipine recommended when these medicinal
Nicardipine Concentrations of calcium channel products are concomitantly
Nifedipine blockers may be increased when administered with Genvoya.
Verapamil co-administered with cobicistat.
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Interaction not studied with any of Alternative endothelin receptor
the components of Genvoya. antagonists may be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nifedipine (HOS-086289) propafenone (HOS-084530) nicardipine (HOS-090619) felodipine (HOS-108908) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) amlodipine (HOS-086287) digoxin (HOS-086172) calcium (HOS-085615) disopyramide (HOS-085595) bosentan (HOS-086291) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage fbc226f308d5b4a973e812dce29188ec92b05700c50154ad831ac93b6af736fa · Zeichen 32099–34742 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-134488 · Präparat HOS-097580
12
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Alfuzosin Based on theoretical considerations Co-administration of darunavir with
darunavir is expected to increase low dose ritonavir and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of The concomitant use with darunavir
alfentanil is mediated via CYP3A, and and low dose ritonavir may require
may as such be inhibited by darunavir to lower the dose of alfentanil and
co-administered with low dose requires monitoring for risks of
ritonavir. prolonged or delayed respiratory
depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Darunavir is expected to Caution is warranted and
Flecainide increase these antiarrhythmic plasma therapeutic concentration
Lidocaine concentrations. monitoring, if available, is
(systemic) (CYP3A and/or CYP2D6 inhibition) recommended for these
Mexiletine antiarrhythmics when co-
Propafenone administered with darunavir with
low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 9518a303c5be83b8c623da21f0ef8178c9138853ea1049de3dcd627347157795 · Zeichen 19313–21059 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-134613 · Präparat HOS-097580
53
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir†
Lopinavir/ritonavir 400/100 lopinavir AUC ↑ 9% Due to a decrease in the exposure
mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%,
lopinavir Cmax ↓ 2% appropriate doses of the combination
have not been established. Hence,
darunavir AUC ↓ 38%‡ concomitant use of boosted darunavir
darunavir Cmin ↓ 51%‡ and the combination product
darunavir Cmax ↓ 21%‡ lopinavir/ritonavir is contraindicated
Lopinavir/ritonavir lopinavir AUC ↔ (see section 4.3).
533/133.3 mg twice daily lopinavir Cmin ↑ 13%
lopinavir Cmax ↑ 11%
darunavir AUC ↓ 41%
darunavir Cmin ↓ 55%
darunavir Cmax ↓ 21%
‡
based upon non dose normalised
values
CCR5 ANTAGONIST
Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be 150
150 mg twice daily maraviroc Cmin ND mg twice daily when co-administered
maraviroc Cmax ↑ 129% with boosted darunavir.
darunavir, ritonavir concentrations
were consistent with historical data
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical considerations Co-administration of boosted
darunavir is expected to increase darunavir and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of The concomitant use with boosted
alfentanil is mediated via CYP3A, darunavir may require to lower the
and may as such be inhibited by dose of alfentanil and requires
boosted darunavir. monitoring for risks of prolonged or
delayed respiratory depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted darunavir is Caution is warranted and ther apeutic
Flecainide expected to increase these concentration monitoring, if
Lidocaine (systemic) antiarrhythmic plasma available, is recommended for these
Mexiletine concentrations. antiarrhythmics when co-
Propafenone (CYP3A and/or CYP2D6 administered with boosted darunavir.
inhibition)
Amiodarone Bepridil Co-administration of boosted
Dronedarone Ivabradine darunavir and amiodarone, bepridil,
Quinidine Ranolazine dronedarone, ivabradine, quinidine,
or ranolazine is contraindicated (see
section 4.3).
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is recommended
digoxin Cmax ↑ 29% that the lowest possible dose of
(↑ digoxin from probable inhibition digoxin should initially be prescribed
of P-gp) in case digoxin is given to patients on
boosted darunavir therapy. The
digoxin dose should be carefully
titrated to obtain the desired clinical
effect while assessing the overall
clinical state of the subject.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) propafenone (HOS-084530) dronedarone (HOS-086144) protease (HOS-085623) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) disopyramide (HOS-085595) maraviroc (HOS-086186) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 737ba554b4078e65ecf09cd520335cc5df12785cb4f30673452d55d887588655 · Zeichen 22720–27726 im Abschnitt
Wechselwirkungen · Kisqali
Kisqali 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-136252 · Präparat HOS-097860
Anti-arrhythmic medicinal products and other medicinal products that may prolong the QT interval
Co-administration of Kisqali with medicinal products with a known potential to prolong the QT
interval such as anti-arrhythmic medicinal products (including, but not limited to, amiodarone,
disopyramide, procainamide, quinidine and sotalol), and other medicinal products that are known to
prolong the QT interval (including, but not limited to, chloroquine, halofantrine, clarithromycin,
ciprofloxacin, levofloxacin, azithromycin, haloperidol, methadone, moxifloxacin, bepridil, pimozide
and intravenous ondansetron) should be avoided (see section 4.4). Kisqali is also not recommended to
be used in combination with tamoxifen (see sections 4.1, 4.4 and 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) methadone (HOS-086198) ciprofloxacin (HOS-085177) tamoxifen (HOS-088380) bepridil (HOS-085612) halofantrine (HOS-085606) quinidine (HOS-085593) azithromycin (HOS-088112) levofloxacin (HOS-128837) disopyramide (HOS-085595) procainamide (HOS-086617) clarithromycin (HOS-084517) pimozide (HOS-085600) moxifloxacin (HOS-085604) haloperidol (HOS-085602) amiodarone (HOS-085596) ondansetron (HOS-086052) chloroquine (HOS-109138)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:22:00Z · SHA-256 808e9743b462916472557a0fc0a032e5a4cdf4c2e48d8fd0f992823e92cc05c1 · Passage 58204aa4622d8004f93cd3949febb145336dedbece94dc5cc46a58898e28a2af · Zeichen 8724–9480 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.